Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.

A retrospective analysis of a personalized tumor-informed ctDNA assay on prospectively collected samples was used to monitor treatment in advanced melanoma. The abstract does not name the manufacturer.

CancerPubMed 36869646DOI 10.1002/cncr.34716